Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

9.66
0.0000
Post-market: 9.660.00000.00%16:15 EST
Volume:744.13K
Turnover:7.12M
Market Cap:492.74M
PE:-2.58
High:9.72
Open:9.60
Low:9.38
Close:9.66
52wk High:12.34
52wk Low:2.24
Shares:51.01M
Float Shares:36.78M
Volume Ratio:1.04
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7446
EPS(LYR):-2.9821
ROE:-45.38%
ROA:-27.64%
PB:1.34
PE(LYR):-3.24

Loading ...

4D Molecular Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Kristian Humer, Chief Financial Officer

Reuters
·
Dec 12, 2025

4D Molecular Therapeutics to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 08, 2025

Chief Legal Officer Scott Bizily Reports Disposal of 4D Molecular Therapeutics Inc. Common Shares

Reuters
·
Nov 20, 2025

4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD

Reuters
·
Nov 20, 2025

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Nov 18, 2025

Stock Track | 4D Molecular Therapeutics Soars 5.19% on Appointment of New CFO Kristian Humer

Stock Track
·
Nov 17, 2025

4D Molecular Therapeutics Names Kristian Humer as CFO

MT Newswires Live
·
Nov 17, 2025

4D Molecular names Kristian Humer as CFO

TIPRANKS
·
Nov 17, 2025

4Dmt Appoints Kristian Humer as Chief Financial Officer

THOMSON REUTERS
·
Nov 17, 2025

Press Release: 4DMT Appoints Kristian Humer as Chief Financial Officer

Dow Jones
·
Nov 17, 2025

4D Molecular Therapeutics Grants 45,400 RSUs to New Employees

Reuters
·
Nov 15, 2025

Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Simply Wall St.
·
Nov 12, 2025

Stock Track | 4D Molecular Therapeutics Soars 5.21% Amid Positive Analyst Updates

Stock Track
·
Nov 11, 2025

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 11, 2025

Morgan Stanley Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Nov 11, 2025

RBC Raises Price Target on 4D Molecular Therapeutics to $32 From $26, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Nov 11, 2025

4D Molecular Therapeutics Inc : RBC Raises Target Price to $32 From $26

THOMSON REUTERS
·
Nov 11, 2025

Chardan Capital Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Nov 11, 2025

4D Molecular Therapeutics Inc : Chardan Capital Markets Raises Target Price to $26 From $25

THOMSON REUTERS
·
Nov 11, 2025

4D Molecular Therapeutics' Q3 revenue misses

Reuters
·
Nov 10, 2025